Total Lymphocyte Count, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio as Prognostic Factors in Advanced Non-Small Cell Lung Cancer with Chemoradiotherapy [Corrigenudm]

Figures & data

Figure 3 Kaplan–Meier plots of overall survival among patients who receivedchemoradiotherapy for advanced NSCLC stratified by baseline PLR.

Abbreviations: NSCLC, non–small cell lung cancer; PLR, platelet-to-lymphocyteratio.

Table 2 Univariate analysis of factors potentially associated with overall survival

Characteristics	HR	95% CI	P Value
Age ≥65	0.778	0.609–0.994	0.045
Male	0.935	0.733–1.193	0.588
KPS score ≥70	1.100	0.762-1.588	0.611
TNM stage IIIB	1.024	0.763-1.375	0.874
Current smoker	0.918	0.748-1.126	0.412
Receipt of induction chemotherapy	1.127	0.881-1.443	0.342
Receipt of concurrent chemotherapy	0.868	0.660-1.143	0.314
Pretreatment TLC ≥2.4 × 10^3/μL	0.594	0.464-0.759	<0.001
Pretreatment NLR ≥3.4	2.280	1.776–2.927	<0.001
Pretreatment PLR ≥136.1	1.745	1.364-2.232	<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

Table 3 Multivariate analysis of factors potentially associated with overall survival Model 1 (TLC included)

	Model 1 (TLC Included)			Model 2 (NLR Included)			Model 3 (PLR Included)
	HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
Characteristics
Age ≥65	0.902	0.697-1.167	0.431	0.858	0.67-1.099	0.226	0.825	0.645-1.054	0.124
Pretreatment TLC ≥2.4 × 10^3/μL	0.613	0.474-0.794	<0.001
Pretreatment NLR ≥3.4				2.231	1.734-2.87	<0.001
Pretreatment PLR ≥136.1							1.71	1.333-2.185	<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.